Switch Therapeutics Revenue and Competitors

Location

#6007

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Switch Therapeutics's estimated annual revenue is currently $4M per year.(i)
  • Switch Therapeutics's estimated revenue per employee is $77,500
  • Switch Therapeutics's total funding is $72M.

Employee Data

  • Switch Therapeutics has 51 Employees.(i)
  • Switch Therapeutics grew their employee count by 65% last year.

Switch Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Switch Therapeutics?

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. \n\nBased on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. \n\nTo date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced.

keywords:N/A

$72M

Total Funding

51

Number of Employees

$4M

Revenue (est)

65%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.5M51-36%N/A
#2
$6.7M51-2%N/A
#3
$6.7M5142%N/A
#4
$11.5M5111%N/A
#5
$6.2M5121%$129M